SAN DIEGO, Calif. /ScoopCloud/ -- ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus's growing HTS screening collection. This collaboration, which utilized Arcus's medicinal chemistry knowledge and ChemDiv's computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.
"A best-in-class drug always starts with a great lead, and our team has learned over the years, going back to our Tularik days, that ChemDiv's libraries have been carefully designed to increase the likelihood of identifying such great leads," said Juan Jaen, President and Co-Founder of Arcus Biosciences.
Jaen added: "Arcus currently has a number of small-molecule discovery programs targeted at the regulation of several biological pathways that appear to play important roles in the suppression of effector immune (T and NK) cells. Some of these programs are already fairly mature and will be in the clinic in short order; however, some of the earlier-stage projects will benefit immensely from having access to ChemDiv's compounds.
"ChemDiv's efficiency in producing high-quality, diverse, and medicinal chemistry-friendly compound collections, coupled with their ability to resupply compounds and build upon those initial hits with their Discovery Chemistry services makes ChemDiv a partner of choice for any organization, large or small, who is looking for a partner in small-molecule drug discovery."
"We are thrilled to have the opportunity to partner with Arcus Biosciences," commented Ron Demuth, General Manager of ChemDiv, Inc. "One of the most promising companies in the very competitive immune-oncology space and one of the few companies engaged in building a broad portfolio of internally designed small-molecule drugs for use in reversing the immunosuppressive tumor microenvironment; our priority is to help our partner by providing access to all the unique features of our expanding compound collection."
ChemDiv is a recognized global leader in discovery chemistry with one of the industry's largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv's integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. More information: http://www.chemdiv.com/.
About Arcus Biosciences:
Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco Bay area, in the heart of the world's largest biotechnology research hub. More information: https://www.arcusbio.com/
Senior VP, Corporate Development & General Manager
ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus's growing HTS screening collection. This collaboration, which utilized Arcus's medicinal chemistry knowledge and ChemDiv's computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.
This version of news story was published on ScoopCloud™ (ScoopCloud.com) - part of the Neotrope® News Network - all rights reserved.